Cargando…
Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
BACKGROUND AND AIMS: Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient absorption in patients with short bowel syndrome (SBS). This...
Autores principales: | Jeppesen, P B, Gilroy, R, Pertkiewicz, M, Allard, J P, Messing, B, O'Keefe, S J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112364/ https://www.ncbi.nlm.nih.gov/pubmed/21317170 http://dx.doi.org/10.1136/gut.2010.218271 |
Ejemplares similares
-
Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn's disease: A European multicentre observational cohort study
por: Tai, Foong Way D., et al.
Publicado: (2021) -
Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome
por: Iyer, Kishore R., et al.
Publicado: (2016) -
Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block
por: Vipperla, Kishore, et al.
Publicado: (2014) -
Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials
por: Seidner, Douglas L., et al.
Publicado: (2019) -
Exit strategies from the COVID-19 lockdown for children and young people receiving home parenteral nutrition (HPN): lessons from the BSPGHAN Intestinal Failure Working Group experience
por: Barclay, Andrew Robert, et al.
Publicado: (2020)